Collaborations: ImmunoGen, Inc.

Home

Company	\|	Date	\|	Type
Amgen		11/09		License of Right to Use TAP Technology for Undisclosed Target
		9/09		License of Right to Use TAP Technology for Undisclosed Target
		9/00		Right to test TAP technology

Genentech*		12/08		License of Right to Use TAP Technology for Undisclosed Target
		12/05		License of Right to Use TAP Technology for Undisclosed Target
		7/05		License of Right to Use TAP Technology for Undisclosed Target
		4/05		License of Right to Use TAP Technology for Undisclosed Target

Bayer HealthCare		10/08		License of Right to Use TAP Technology for Undisclosed Target

sanofi-aventis		8/08		Exercise of Option for Expanded Access to ImmunoGen's TAP Technology
		10/06		License for Broader Access to ImmunoGen's Humanization Technology
		8/06		Second extension of 7/03 research collaboration; release of ImmunoGen from presenting targets
		7/03		Research, development, and commercialization collaboration

Biotest		7/06		License of Right to Use TAP Technology for Undisclosed Target; ImmunoGen Has Opt-In Rights

Genentech		5/06		ImmunoGen to develop commercial-scale manufacturing process for T-DM1; amendment of 5/00 HER2 agreement
Genentech		5/00		License of Right to Use TAP Technology for HER2 target

Biogen Idec		10/04		License of Right to Use TAP Technology for Undisclosed Target

*Genentech, Inc. is a member of the Roche Group.

Last updated July 7, 2010